- Home
- DAWN
as 03-25-2025 10:34am EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.2B | IPO Year: | 2021 |
| Target Price: | $32.29 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.88 - $18.07 | Next Earning Date: | 05-05-2025 |
| Revenue: | $131,161,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 28.72% | Revenue Growth (next year): | 73.78% |
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dubow Adam | DAWN | GENERAL COUNSEL | Feb 15 '25 | Sell | $11.96 | 4,646 | $55,580.10 | 39,602 | |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | Feb 15 '25 | Sell | $11.96 | 12,048 | $144,130.22 | 128,015 | |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | Feb 15 '25 | Sell | $11.96 | 4,370 | $52,278.31 | 252,638 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
WWD
6 days ago
EXCLUSIVE: Plant Medicine Brand Apothékary Is Taking Customers on a $10,000 Immersive Trip to Japan
Simply Wall St.
16 days ago
High Growth Tech Stocks In The US With Promising Potential
Insider Monkey
21 days ago
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory
Zacks
a month ago
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Zacks
a month ago
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
GuruFocus.com
a month ago
Day One Biopharmaceuticals Inc (DAWN) Q4 2024 Earnings Report Preview: What To Look For
Zacks
a month ago
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
Compare DAWN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.